Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients

American Journal of Psychiatry

Volumn 159, Issue 7, 2002, Pages 1165-1173

  Gluck, Martin R ^a   Thomas, Rohan G ^a   Davis, Kenneth L ^a   Haroutunian, Vahram ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE DEHYDROGENASE; GLUTAMIC ACID; GLUTAMINASE; OXOGLUTARATE DEHYDROGENASE; SUCCINATE SEMIALDEHYDE DEHYDROGENASE;

4 AMINOBUTYRIC ACID METABOLISM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; PH; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA;

AGE FACTORS; AGED; CITRATE (SI)-SYNTHASE; FEMALE; FUNCTIONAL LATERALITY; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; GLUTAMINASE; HUMANS; MALE; POSTMORTEM CHANGES; PREFRONTAL CORTEX; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0036307527     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.7.1165     Document Type: Article

References (59)

1. The current status of the dopamine hypothesis of schizophrenia
2. Glutamate receptor dysfunction and schizophrenia
3. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
4. The neurochemistry of schizophrenia
5. Glutamatergic aspects of schizophrenia
6. Recent advances in the phencyclidine model of schizophrenia
7. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
8. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
9. The neuropathology of schizophrenia: A critical review of the data and their interpretation
10. A glutamatergic deficiency model of schizophrenia
11. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
12. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
13. N-Methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia
14. Pharmacological animal models of dementia
15. Reduced GABA uptake sites in the temporal lobe in schizophrenia
16. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses
17. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics
18. 67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia
19. Muscimol: GABA agonist therapy in schizophrenia
20. Emerging principles of altered neural circuitry in schizophrenia
21. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives
22. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
23. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
24. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia
25. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain
26. Local circuit neurons of the prefrontal cortex in schizophrenia: Selective increase in the density of calbindin-immunoreactive neurons
27. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia
28. Cytoarchitectonic definition of prefrontal areas in the normal human cortex, 1: Remapping of areas 9 and 46 using quantitative criteria
29. A connectionist approach to the prefrontal cortex
30. Abnormally high neuronal density in the schizophrenic cortex
31. Prefrontal cortical dysfunction in schizophrenia: The relevance of working memory
32. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine
33. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
34. Alzheimer's disease and related neurodegenerative diseases in elderly schizophrenic patients
35. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients
36. L-Glutamate dehydrogenase from bovine liver
37. A rapid radioactive assay for glutamine synthetase, glutaminase, asparagine synthetase, and asparaginase
38. Glutamine synthetase from muscle
39. Optimization of methods for aspartate aminotransferase and alanine aminotransferase
40. Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype
41. Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases
42. Gamma-aminobutyrate aminotransferase activity in brains of schizophrenic patients
43. Human brain "high Km" aldehyde dehydrogenase: Purification, characterization, and identification as NAD+-dependent succinic semialdehyde dehydrogenase
44. Mitochondrial complex I deficiency in Parkinson's disease
45. Protein measurement with folin reagent
46. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine: Evidence for interaction at the glutamine binding site
47. Two isoforms of glutamate decarboxylase: Why?
48. Functional and molecular dysregulation of GABA systems in DLPFC of schizophrenics
49. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia
50. Correlations of regional postmortem enzyme activities with premortem local glucose metabolic rates in Alzheimer's disease
51. Distribution of phosphate-activated glutaminase in the human cerebral cortex
52. Postmortem human brain pH and lactate in sudden infant death syndrome
53. The patients dying after long terminal phase have acidotic brains: Implications for biochemical measurements on autopsy tissue
54. Persistence of haloperidol in human brain tissue
55. Antipsychotic regulation of hippocampal dopamine receptor messenger RNA expression
56. Up-regulation of tyrosine hydroxylase mRNA in a sub-population of A10 dopamine neurons in Parkinson's disease
57. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
58. 67) expression in schizophrenia and bipolar disorder: A postmortem brain study
59. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain